Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage.

Curr Opin Immunol

Division of Rheumatology, Center of Inflammation, Immunity and Regenerative Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908, United States. Electronic address:

Published: December 2014

Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disorder. Considerable progress has been made to delineate the genetic control of this complex disorder. In this review, selected aspects of human and mouse genetics related to SLE are reviewed with emphasis on genes that contribute to both innate and adaptive immunity and to genes that contribute directly to susceptibility to end organ damage. It is concluded that the interactions among these two major pathways will provide further insight into the pathogenesis of SLE. An interactive model of the two major pathways is proposed without emphasis on the importance of breaking tolerance to autoantigens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274270PMC
http://dx.doi.org/10.1016/j.coi.2014.10.004DOI Listing

Publication Analysis

Top Keywords

systemic lupus
8
lupus erythematosus
8
genes contribute
8
major pathways
8
genetics systemic
4
erythematosus immune
4
immune responses
4
responses organ
4
organ resistance
4
resistance damage
4

Similar Publications

Women are disproportionately affected by chronic autoimmune diseases (AD) like systemic lupus erythematosus (SLE), scleroderma, rheumatoid arthritis (RA), and Sjögren's syndrome. Traditional evaluations often underestimate the associated cardiovascular disease (CVD) and stroke risk in women having AD. Vitamin D deficiency increases susceptibility to these conditions.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease often treated with glucocorticoids, which can lead to complications such as osteoporosis and an increased infection risk. Hence, identifying safe and effective treatment strategies is crucial. has shown promise in improving immune disorders.

View Article and Find Full Text PDF

The 2024 APLAR Consensus on the Management of Lupus Nephritis.

Int J Rheum Dis

January 2025

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus nephritis (LN) according to two rounds of Delphi exercise from members of the APLAR SLE special interest group, invited nephrologists, histopathologists, and lupus nephritis patients. For initial treatment of LN, we recommend a combination of glucocorticoids (GCs) with cyclophosphamide (CYC), mycophenolate mofetil (MMF), or the calcineurin inhibitors (CNIs) as first-line options.

View Article and Find Full Text PDF

Introduction: Despite progress in systemic lupus erythematosus (SLE) treatment, challenges persist in medication adherence due to side effects and costs. Precision nutrition, particularly adjusting fatty acid intake, offers a cost-effective strategy for enhancing SLE management. Prior research, including our own, indicates that increased consumption of omega-3 polyunsaturated fatty acids (PUFAs) correlates with improved outcomes in SLE patients.

View Article and Find Full Text PDF

Whether autoimmune diseases caused any effects on the risk of cancers remained yet clarified. This study aimed to investigate the causal effect of autoimmune diseases on pan-cancers through mendelian randomization (MR) analysis. The GWAS summary datasets of 10 autoimmune diseases were derived from the IEU or UK biobank website.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!